UPBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Upstream Bio, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$2.80+0.04 (+1.45%)
Close on Oct 19, 2026
- Market cap
- $152.79M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$18.17 (−86.65%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Upstream Bio, Inc. grew revenue 16.0% to $3.16M over the twelve months to Jun 30, 2026. Free cash flow was -$133.44M.
Revenue
$3.16M
+16.0% vs. a year earlier
Operating income
-$169.98M
TTM Q2 2026
Free cash flow
-$133.44M
FY2025
EPS, diluted
-$2.89
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $152.79M
- P/E ratio
- –
- Price to sales
- 48.38
- Price to book
- 0.56
- Dividend yield
- –
- Free cash flow yield
- -87.34%
Fundamentals
- Revenue
- $3.16M
- Net income
- -$156.50M
- EPS, diluted
- -$2.89
- Free cash flow
- -$133.44M
- Book value per share
- $4.97
- Diluted shares
- 55M
Four years at a glance
Fiscal years 2022 to 2025 and trailing twelve months, USD
Revenue
$3.16M+16.0% YoY
Operating income
-$169.98M
Net income
-$156.50M
EPS, diluted
-$2.89
Free cash flow
–
Reported periodTrailing twelve months